Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
P
187660
vs
K
KOSPI 200
Over the past 12 months, Penetrium Bioscience Inc has significantly outperformed KOSPI 200, delivering a return of +123% compared to KOSPI 200's +35% growth.
Stocks Performance
187660 vs KOSPI 200
Performance Gap
187660 vs KOSPI 200
Create a free account · No card needed
Performance By Year
187660 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Penetrium Bioscience Inc
Glance View
ADM Korea is a contract research organization that helps drug makers run clinical trials in Korea. It supports the work needed to test new medicines, including trial planning, regulatory paperwork, site coordination, data handling, and study management. Its customers are pharmaceutical companies, biotech firms, and other drug developers that need help moving a medicine from development into human testing. The company makes money by charging project fees for each study or service package it handles. In simple terms, ADM Korea does not sell a drug of its own; it sells the specialized people and systems needed to run trials correctly and on schedule. That makes its revenue tied to the number and type of development projects it wins from clients. What sets its business apart is its role in the drug-development chain. It sits between the sponsor that wants to develop a medicine and the hospitals and investigators that enroll patients and collect trial data. That puts ADM Korea in a service-heavy, regulated niche where trust, compliance, and operational execution matter more than manufacturing scale.
Create a free account · No card needed